The first head-to-head randomized trial of semaglutide and tirzepatide for obesity, SURMOUNT-5, reported its results in 2025 — and the gap was wider than most clinicians expected. After 72 weeks, patients on tirzepatide 15 mg lost an average of 20.2% of their body weight, compared with 13.7% on semaglutide 2.4 mg.1 That 6.5-percentage-point difference is not a rounding error. It is the difference between losing 30 pounds and losing 45 pounds on a 220-pound starting weight.

But raw weight loss is only part of the story. The two medications differ in their mechanism, side-effect profile, cost, and — importantly — in which patients respond best to each. This article walks through the published evidence and the receptor pharmacology that explains the gap.

Two molecules, two mechanisms

Semaglutide (Wegovy, Ozempic) is a single-agonist medication: it activates only the GLP-1 receptor. Tirzepatide (Zepbound, Mounjaro) is a dual agonist: it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.

For years, GIP was considered a pharmacological dead end — chronically elevated GIP in obese patients was thought to promote fat storage, not fat loss. That view has been overturned. Recent work suggests that simultaneous GIP and GLP-1 agonism produces synergistic effects on energy expenditure, lipid handling in adipose tissue, and central appetite signaling that neither receptor achieves alone.2 Tirzepatide also produces somewhat less nausea per unit of weight loss, which the SURPASS investigators have attributed to GIP's apparent dampening effect on the nausea-and-vomiting pathways activated by GLP-1.3

What the head-to-head trial found

SURMOUNT-5 enrolled 751 adults with obesity (BMI ≥ 30) or overweight with weight-related complications (BMI ≥ 27), without type 2 diabetes. Participants were randomized to maximum tolerated doses of either drug for 72 weeks. The key results:

  • Mean weight loss: tirzepatide 20.2%, semaglutide 13.7% (difference 6.5 percentage points, p < 0.001).1
  • ≥15% weight loss: achieved by 64.6% of tirzepatide patients versus 40.1% of semaglutide patients.
  • ≥25% weight loss: achieved by 31.6% of tirzepatide patients versus 16.1% of semaglutide patients.
  • Waist circumference reduction: 18.4 cm tirzepatide vs. 13.0 cm semaglutide.
  • Discontinuation due to adverse events: 6.1% tirzepatide vs. 8.0% semaglutide — slightly in tirzepatide's favor.

The most common side effects in both arms were gastrointestinal — nausea, diarrhea, constipation — and were rated mild to moderate in over 80% of cases. Severe events were rare.

Cardiovascular and metabolic effects

Semaglutide carries the stronger cardiovascular outcomes label. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and obesity, leading to the FDA's 2024 cardiovascular risk-reduction indication.4 Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with topline data expected in 2027. Until then, tirzepatide's cardiovascular benefits are inferred from surrogate markers — blood pressure, lipids, inflammatory markers — all of which improve substantially.5

For glycemic effects, both drugs are highly effective, but tirzepatide produces a roughly 0.5% greater HbA1c reduction in head-to-head diabetes trials (SURPASS-2).6

So why doesn't every patient take tirzepatide?

Several reasons:

  1. Insurance and access. Coverage for tirzepatide for obesity (Zepbound) remains spottier than coverage for semaglutide (Wegovy), particularly through commercial plans and Medicare.
  2. Cardiovascular indication. Patients with established cardiovascular disease may benefit from the evidence-backed MACE reduction semaglutide offers today.
  3. Tolerability is individual. Mean adverse-event rates hide wide variation. A subset of patients tolerate semaglutide well but cannot stay on tirzepatide, and vice versa.
  4. Maintenance vs. induction. Some clinicians use tirzepatide for active weight loss and transition to semaglutide for long-term maintenance, citing semaglutide's longer real-world safety record and cardiovascular data.

What the receptor pharmacology suggests about responders

Genome-wide association work on GLP-1 response is still preliminary, but emerging data suggest that variants in GLP1R and GIPR may help explain why some patients lose 25% of their body weight on tirzepatide while others on the same dose plateau at 8%.7 Until pharmacogenomic testing is clinically validated, the practical implication is unglamorous but important: response is best assessed empirically, on the patient, with a clinician adjusting dose and titration pace based on tolerability and trajectory — not by assuming the trial mean applies to any individual.

Practical takeaways

  • If raw weight loss is the priority and the patient can access it, tirzepatide produces meaningfully greater loss on average — about 1.5x as much in head-to-head data.
  • If the patient has established cardiovascular disease, semaglutide currently has the only FDA-approved MACE-reduction indication in this class.
  • Side-effect profiles overlap heavily but are individual; trial of dose escalation matters more than picking the "right" molecule on paper.
  • Both medications work best inside a protocol that includes protein-forward nutrition, resistance training, and clinical monitoring of body composition — not just scale weight.

For patients trying to navigate this choice, the medication is only half the question. The other half is whether the clinical program around it is set up to preserve lean mass, monitor metabolic markers, and adjust dose intelligently. Patients exploring personalized GLP-1 therapy can consult with the medical team at Teleios Health, which structures GLP-1 programs around body composition and long-term metabolic outcomes rather than scale weight alone.

References

  1. Aronne LJ, et al. Tirzepatide versus Semaglutide for Weight Loss in Adults with Obesity (SURMOUNT-5). New England Journal of Medicine. 2025;392:1631-1642.
  2. Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends in Endocrinology & Metabolism. 2020;31(6):410-421.
  3. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
  4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
  5. Eli Lilly & Co. SURPASS-CVOT trial design (NCT04255433). Estimated primary completion: October 2027.
  6. Frías JP, et al. SURPASS-2 cited above; HbA1c reductions of 2.0–2.3% (tirzepatide) vs. 1.9% (semaglutide 1 mg).
  7. Karagiannis T, et al. Pharmacogenetics of GLP-1 receptor agonists: a state-of-the-art review. Diabetologia. 2024;67:589-603.

This article is for educational purposes and does not constitute medical advice. GLP-1 medications require clinical supervision and should not be started, stopped, or switched without consulting a qualified healthcare professional.